Skip to main content
Caplight Logo









Corxel

Corxel

Private
ShanghaiHealthcare & Life Scienceshttps://corxel.com/

Last Round

Series D

Extension

Jan 22, 2026

Total Funding Raised

$489M

Company Overview

Corxel is a biopharmaceutical company that in-licenses and develops clinical-stage assets to treat cardiometabolic and cardiovascular diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug developmentclinical trialscardiometabolic diseasein-licensingsmall-molecule drugsGLP-1 receptor agonistbiotech pipelineasset-focused biotechclinical-stagepharma licensingdrug discoveryobesity treatmentGreater China commercializationbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Corxel Comparables

Compare Corxel with similar companies based on industry and business-model similarity.

Corxel comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zhejiang Jixing Auto Parts Co., Ltd.
97%
Gmax Biopharm
81%
Sciwind Biosciences
80%

Corxel Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series D ExtensionJan 22, 2026
Series DJan 6, 2024
Series CSep 1, 2021
Series BJul 13, 2021

Corxel Investors

Notable investors and investment history

Corxel investors
InvestorRounds
Hengdian Group CapitalSeries D Extension
SymBiosis Capital ManagementSeries D Extension
RA Capital ManagementSeries D Extension
TCG CrossoverSeries D Extension
HBM Healthcare InvestmentsSeries D Extension
Adage Capital ManagementSeries D Extension
SilverArc Capital ManagementSeries D Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 6, 2024

    $162M round led by Leaps by Bayer and RTW Investments.

Corxel Filings

Explore SEC and related filing metadata, where available.

Corxel filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Corxel's valuation, stock price, and market status.

Is Corxel a public or private company?

Corxel is a private company.

What is the current stock price of Corxel?

Corxel is a private company with no public stock price. No recent secondary market data is available.

How much is Corxel worth (valuation)?

Valuation information for Corxel is not publicly available.

Can I buy Corxel stock?

Corxel shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Corxel's last funding round?

Corxel's most recent funding round was Series D Extension on January 22, 2026.

Who are the main investors in Corxel?

Key investors in Corxel include RTW Investments, Leaps by Bayer.

Will Corxel IPO soon?

No public IPO plans have been announced for Corxel.

How can I track Corxel secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Corxel's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Year Founded2019
Last FundingJan 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?